Energy metabolism and biotransformation as endpoints to pre-screen hepatotoxicity using a liver spheroid model

Toxicology and Applied Pharmacology

Volumn 216, Issue 2, 2006, Pages 293-302

  Xu, Jinsheng ^a   Purcell, Wendy M ^b  

^a UNIVERSITY OF THE WEST OF ENGLAND   (United Kingdom)

^b UNIVERSITY OF HERTFORDSHIRE   (United Kingdom)

Author keywords

Galactose; Glucose; Hepatotoxicity; Lactate; Liver spheroids; Pyruvate

Indexed keywords

1,3 DINITROBENZENE; ANILINE DERIVATIVE; DICLOFENAC; GALACTOSAMINE; GALACTOSE; GLUCOSE; ISONIAZID; LACTIC ACID; PARACETAMOL; PYRUVIC ACID;

ANIMAL CELL; ARTICLE; BIOTRANSFORMATION; CELL TRANSFORMATION; CONTROLLED STUDY; DRUG EXPOSURE; ENERGY METABOLISM; LIVER CELL; LIVER METABOLISM; LIVER TOXICITY; MALE; NONHUMAN; RAT; SCREENING; STATISTICAL SIGNIFICANCE;

ANIMALS; BIOTRANSFORMATION; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; ENDPOINT DETERMINATION; ENERGY METABOLISM; GLUCOSE; HEPATOCYTES; LACTIC ACID; MALE; PYRUVIC ACID; RATS; RATS, WISTAR; SPHEROIDS, CELLULAR; TOXICITY TESTS; XENOBIOTICS;

EID: 33749068665     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2006.05.015     Document Type: Article

References (42)

1. Anadan R., and Devaki T. Biochemical studies on the anti-hepatotoxic potential of Picrohiza kurroa on mitochondrial damage in d-galactosamine-induced liver intoxication in rate. Med. Sci. Res. 26 (1998) 349-352
2. Barlow P.B., Black M., Brummer D.L., Comstock G.W., Dubin I.N., Enterline P., Gibson M.L., Hardy Jr. G.E., Harrel J.A., Johnston R.E., Mosley J.W., Ogasawara F.R., Poper H., Reichman L.B., and Zimmerman H.J. Preventive therapy of tuberculous infection. Am. Rev. Respir. Dis. 110 (1974) 371-374
3. Berg J.M., Tymoczko J.L., and Stryer L. Glycolysis and gluconeogenesis. Chapter 16, Biochemistry. 5th ed. (2002), W. H. Freeman and Company, New York 425-464
4. Boelsterli U.A. Diclofenac-induced liver injury: a paradigm of idiosyncratic drug toxicity. Toxicol. Appl. Pharmacol. 192 (2003) 307-322
5. Bort R., Ponsoda X., Jover R., Gomez-Lechon M.J., and Castell J.V. Diclofenac toxicity to hepatocytes: a role for drug metabolism in cell toxicity. J. Pharmacol. Exp. Ther. 288 (1999) 65-72
6. Burcham P.C., and Harman A.W. Acetaminophen toxicity results in site-specific mitochondrial damage in isolated mouse hepatocytes. J. Biol. Chem. 266 (1991) 5049-5054
7. Cody T.E., Witherup S., Hastings L., Stemmer K., and Christian R.T. 1.3-Dinitrobenzene. Toxic effects in vivo and in vitro. J. Toxicol. Environ. Health 7 (1981) 829-847
8. Cossum P.A., and Rickert D.E. Metabolism of dinitrobenzenes by rat isolated hepatocytes. Drug Metab. Dispos. 13 (1985) 664-668
9. Cossum P.A., Rickert D.E., and Working P.K. Comparison of the testicular toxicity of the dinitrobenzenes and their major reduced metabolites in the rat. The Pharmacologist 28 (1986) 178
10. Dahlin D.C., Miva G.T., Lu A.Y.H., and Nelson S.D. N-acetyl-P-benzoquinone imine: a cytochrome P-450 mediated oxidation product of acetaminophen. Biochemistry 81 (1984) 1327-1331
11. DiazBuxo J.A., Blumenthal S., Hayes D., Gores P., and Gordon B. Galactosamine-induced fulminant hepatic necrosis in unanesthetized canine. Hepatology 25 (1997) 950-957
12. Farrell J., and Schmitz P.G. Paracetamol-induced pancreatitis and fulminant hepatitis in a hemodialysis patient. Clin. Nephrol. 48 (1997) 132-133
13. Fernández T.R.L., Suzuki-Kemmelmeier F., Prado E.C., and Bracht A. The heterogeneous response of the bivascularly perfused rat liver to adenosine. Biochem. Pharmacol. 58 3 (1999) 397-409
14. Friedemann T., and Haugen G.E. Pyruvic acid: II The determination of ketoacids in blood and urine. J. Biol. Chem, 147 (1943) 415
15. Hackstein H., Mohl W., Puschel W., Stallmach A., and Zeitz M. Acute cholestatic hepatitis associated with diclofenac. Z. Gastroenterol. 36 (1998) 385-389
16. Hardwick S.J., Wilson J.W., Fawthrop D.J., Boobis A.R., and Davies D.S. Paracetamol toxicity in hamster isolated hepatocytes-The increase in cytosolic calcium accompanies, rather than precedes, loss of viability. Arch. Toxicol. 66 (1992) 408-412
17. Hartter D.R. The use and importance of nitroaromatic chemicals in the chemical industry. In: Rickert D.E. (Ed). Toxicity of Nitroaromatic Compounds (1985), Hemisphere Publishing Corporation, Washington, DC 1-13
18. Keppler D., Rudigier J.F.M., Bischoff E., and Decker K. The trapping of uridine phosphates by d-galactosamine, d-glucosamine and 2-deoxy-d-galactose. Eur. J. Biochem. 17 (1970) 246-253
19. Ma M., Xu J., and Purcell W.M. Biochemical and functional changes of rat liver spheroids during spheroid formation and maintenance in culture: I. Morphological maturation and kinetic changes of energy metabolism, albumin synthesis and activities of some enzymes. J. Cell. Biochem. 90 (2003) 1166-1175
20. Malojcic B., Brinar V., Poser C., and Djakovic V. An adult case of Leigh disease. Clin. Neurol. Neurosurg. 106 (2004) 237-240
21. Masubuchi Y., Nakayama S., and Horie T. Role of mitochondrial permeability transition in diclofenac-induced hepatocyte injury in rats. Hepatology 35 (2002) 544-551
22. McEuen S.F., and Miller M.G. Metabolism and pharmacokinetics of 1,3-dinitrobenzene in the rat and the hamster. Drug Metabol. Dispos. 19 (1991) 661-666
23. McMillan J.M., and Jollow D.J. Galactosamine hepatotoxicity: effect of galactosamine on glutathione resynthesis in rat primary hepatocyte cultures. Toxicol. Appl. Pharmacol. 115 (1992) 234-240
24. Nazareth W.M.A., Sethi J.K., and McLean A.E.M. Effect of paracetamol on mitochondrial-membrane function in rat-liver slices. Biochem. Pharmacol. 42 (1991) 931-936
25. Noda A., Noda H., Misaka A., Sumimoto H., and Tatsumi K. Hydrazine radical formation catalysed by rat microsomal NADPH-cytochrome P-450 reductase. Biochem. Biophys. Res. Commun. 153 (1988) 256-260
26. Philbert M.A., Nolan C.C., Cremer J.E., Tucker D., and Brown A.W. 1.3-Dinitrobenzene-induced encephalopathy in rats. Neuropathol. Appl. Neurobiol. 13 (1987) 371-389
27. Ponsoda X., Bort R., Jover R., Gómez-Lechón M.J., and Castell J.V. Molecular mechanism of diclofenac hepatotoxicity: association of cell injury with oxidative metabolism and decrease in ATP levels. Toxicol. In Vitro 9 (1995) 439-444
28. Rijcken W.R.P., Ferwerda W., Vandeneijnden D.H., and Overdijk B. Influence of d-galactosamine on the synthesis of sugar nucleotide and glycoconjugates in rat hepatocytes. Glycobiology 5 (1995) 495-502
29. Ruepp S.U., Tonge R.P., Shaw J., Wallis N., and Pagnan F. Genomics and proteomics: analysis of acetaminophen toxicity in mouse liver. Toxicol. Sci.: Official J. Soc. Toxicol. 65 (2002) 135-150
30. Sarich T.C., Adams S.P., and Wright J.M. The role of l-thyroxine and hepatic reductase activity in isoniazid-induced hepatotoxicity in rabbits. Pharmacol. Res. 38 (1998) 199-207
31. Schmeisch A.P., Silva de Oliveira D., Ide L.T., Suzuki-Kemmelmeier F., and Bracht A. Zonation of the metabolic action of vasopressin in the bivascularly perfused rat liver. Regul. Pept. 129 (2005) 233-243
32. Sumida K.D., Crandall S.C., Chadha P.L., and Qureshi T. Differential effects of alcohol upon gluconeogenesis from lactate in young and old hepatocytes. Exp. Gerontol. 40 (2005) 324-329
33. Tee L.B., Davise D.S., Seddon C.E., and Boobis A.R. Species differences in the hepatotoxicity of paracetamol are due to differences in the rate of conversion to its cytotoxic metabolite. Biochem. Pharmacol. 36 (1987) 1041-1052
34. Timbrell J.A. Principles of Biochemical Toxicology (1982), Taylor & Francis Ltd., London 213-214
35. Tonge R.P., Kelly E.J., Bruschi S.A., Kalhorn T., Eaton D.L., Nebert D.W., and Nelson S.D. Role of CYP1A2 in the hepatotoxicity of acetaminophen: investigations using Cyp1a2 null mice. Toxicol. Appl. Pharmocol. 153 (1998) 102-108
36. Wang A.G., Xia T., Yuan J., Yu R.A., Yang K.D., Chen X.M., Qu W., and Waalkes M.P. Effects of Phenobarbital on metabolism and toxicity of diclofenac sodium in rat hepatocytes in vitro. Food Chem. Toxicol. 42 (2004) 1647-1653
37. Webster P.A., Roberts D.W., Benson R.W., and Kearns G.L. Accetaminophen toxicity in children: diagnostic conformation using a specific antigenic biomarker. J. Clin. Pharmacol. 36 (1996) 397-402
38. Xu J., Nolan C.C., Lister T., Purcell W.M., and Ray D.E. Pharmacokinetic factors and concentration-time threshold in m-dinitrobenzene-induced neurotoxicity. Toxicol. Appl. Pharmacol. 161 (1999) 267-273
39. Xu J., Ma M., and Purcell W.M. Optimising the enzymatic determination of galactose in the culture media of rat liver and HepG2 cell spheroids. Anal. Biochem. 311 (2002) 179-181
40. Xu J., Ma M., and Purcell W.M. Characterisation of some cytotoxic endpoints using rat liver and HepG2 spheroids as in vitro models and their application in hepatotoxicity studies: I. glucose metabolism and enzyme release as cytotoxic markers. Toxicol. Appl. Pharmacol. 189 (2003) 100-111
41. Xu J., Ma M., and Purcell W.M. Characterisation of some cytotoxic endpoints using rat liver and HepG2 spheroids as in vitro models and their application in hepatotoxicity studies: II. spheroid cell spreading inhibition as a new cytotoxic marker. Toxicol. Appl. Pharmacol. 189 2 (2003) 112-119
42. Xu J., Ma M., and Purcell W.M. Biochemical and functional changes of rat liver spheroids during spheroid formation and maintenance in culture: II. Nitric oxide synthesis and related changes. J. Cell. Biochem. 90 (2003) 1176-1185